日本消化器外科学会教育集会

(1)

5B>42(7G#/0E8?GF(

6DH(7G-1+$

÷-SVZW#ÊbâaÖmg

Ú | ó

)&,'

·¥¡-@fÛ´@(OEFñ`@û ë;(87Æ?A!(MKOªÿ?·¥¡-GMP7"2,2!Medical oncology @ãw<< I?!!Øg_Jéºû_-Öq?Å2 :dnéºûëR¶zÐ?>*L*?>8 7"~A!dnéºûëÝ.?AÖq@ û¹øAP>)" ÚíÖo}xi@ÖqûUTXYTZ @Ê@á&Öq@±Ó<ûêë@»È'@ Ê;!T4!N4!M1ªÿ?9):AÍ¬>QP Oû<2:·¥¡A»BP:)>)"0PM RÓ±q<2:!dnéºûëRÊ®?6 @ûê²Rj¸3O"(Q5:!dnéºû ë@^JÜ?Å3Oû?9):j¸3 O"

I!5B>42

1!T4"9.A3*(=; ·¥¡-@fÛ´@(OEFñ`@û ë;(87Æ?A!T4ªÿ?Å2:IÇÕî å·¥Jupå·¥>=?LO·¥¡-GMP7"2,2!)åªöJaìö ?I,,QM4!ËtµÂR×O0<AÙ2,8 7"6@7H!T4ªÿ?Å2:A\¿s@å ·¥A>Q4?À·¥¡R)!^27 !?Å2:¡?éº©-QP:.7 -!ô@l½A×MP>,87"dnéºû ë@±ç?LN!~;A T4ªÿ?Å2:·¥ ¡-£kû@»È<>O0<A§>/>8 7"2,2!dnéºûë@y¤³ýAä ;A>/!·¥¡<¾GQ57nÐû-GMP:)O" 1$:@/0E8?GF T4ªÿ?Å2:dnéºûë?LNqR ¦15$down-staging%!\¿s@å·¥R2 >/:I·¥fÛ<>OL*?2:·¥R >*<)*¹ø;(O"ÇÇn@ðïMA!T4 ªÿ?Å2:40Gy @dnéºûëR)!·¥ fÛ<>87ªÿ?A·¥¡R871%_"·¥ ¡28ÿÊ20ÿ; R0¡-fÛ;(87"·¥ÿ Aà·¥ÿ?ßD:µÂö-ò]?ü;(N! down-staging-×MP7ªÿ?A·¥¡R ú3D.<2:)O"ðïM@Á.@è;A! uÖ{C@°¢@(87ªÿAuÖ{[mC@° ¢@(87ªÿ?ßD:!dnéºûë@þ¨ Ðòö-Î/!·¥ö-Î/!·¥ÿ;I R0 @¡-§>/!âõnÐhIÎ/!y¤Ü ö-,872%_{"uÖ{C@°¢ÿ;Adné} ºûë@·¥¡@ÑcA¯;(OD.<2 :)O" ÇäÇn@ïMI!T4ªÿ?Å2:40Gy @ dnéºûëR)!·¥fÛ<>87ªÿ? ·¥¡R+0>)!6@Ã?A20Gy @©RÌ e273%_{"µÂöA·¥ÿ-ò]?ü,87"r} Çn@ÉÒMA!T4Öq?Å2:60Gy @dn éºûëR)!·¥fÛ<>87ªÿ?·¥ ¡R874%_{"·¥ÿAà·¥ÿ?ßDò]?} µÂö-ü;(87" 0@L*?!Q-;A T4Öq?Å2:dn éºûëR)!down-staging R×MP7« ?A¶zÐ?·¥¡R*<3Oè-Ä) -!ÞÏÐèI(O"vùæÇn@ÔÒMA! T4ªÿ?Å2:¡¼?dnéºûëR*,!

<

C

%

(2)

¥ªMÁ3ª?luí¤ÂúîM),@ã t M:85%_{"luí¤Âúî?¿®¥ª} M:815þÒ11þ- R0@£¿®-nâ< ':8"¼ÈøAªÄluí¤Âúî<óc? û<':81=,H!T4²þ?Ë4JÎ 1 ÃÐ AªÄluí¤Âúî<'J=3;(J"73 ;!ªÄluí¤Âúî-ó<':8²þ@) 9!¿®¥ªM:8²þ=¿®¥ªML> ,:8²þ@¼Èø?->,:81=,H!g .Ç. T4²þ?Ë3;36Gy @luí¤Âúî ?¿®¥ªM),!¿®¥ªA65?£ü@ luí¤ÂúîM),@ãt M:86%_" ªÄluí¤Âúî?¿®¥ªM:830þÒ 18þ- R0@£¿®-nâ<':8"3,3!l uí¤Âúî?¨¯MÝHK8²þ<F¨¯M ÝHK>,:8²þ<F!7@?¿®¥ªM :8²þ=£ü@luí¤ÂúîM:8² þ=@¼Èø?MßE>,:81=,H!T4 ¶Üy?Ë3;Aluí¤Âúî-Î 1 ÃÐ< 'J=3;(J"3,3!ªÄluí¤Âúî ?¨¯MßE>,:8²þ@)9!¥ªM:8 11þÒ@ 3 þ- R0@£¿®-nâ<':81 =,H!¿®¥ª? Salvage =3;@c|A'J =3;(J" jê,HA T4²þ?Õ38ìA>("\` P#@ Lerut @ Q ` # [ A!T3-4@ Locally ad-vanced@¶Üy?Ë3;36-40Gy @luí¤Â úî?¿®¥ªM:87%_"£úÄ·ÑA

T4-61&<':8-!¿®@ç÷·Ñ<A T4A14& <'I!24&-Åµu× CR =>I!down-staging -ÝHK8=3;(J"ZOY@ Stahl HA!Lo-cally advanced@¶Üy?Ë3;40Gy @luí ¤Âúî?¿®¥ªM:8²þ=65Gy @ £×luí¤ÂúîM:8²þ@ý°ãt M(!¼Èø?A->,:88%_"luí¤Âú î?¿®¥ªMm*;F!¼Èø@´AF8 H2>(=3;(J"9>C? T4²þA172þÒ 29þ<'I!Locally advanced A T4Mcï3;( >(" b´@ì,H!T4²þ?Ë4J¬q£úAl uí¤Âúî-ÎeÃÐ=*HKJ"down-stagingMÝHK8²þ?Ë3;¿®¥ªM) ,!¿®¥ª@Ë³=65£×luí¤Âúî M>),@!A©;(>(" 2!$%("#)&'+* luí¤Âúî@¸ë?GI!å¥ªúî=3 ;luí¤Âúî-/LKJG)?>:;. 8"T4²þ?Ë3;F!¿®¥ªMÄÖ=65 full-dose@luí¤Âéöúî->LK;( J"ù-NVaW#Úçh@ÍÔHA!Locally advanced@¶Üy?Ë3;Û¢éöluí¤Â úîME89%_{"3,3!Óð>iÞºMßE8} 8E}zwMD£úURT]#`?sû3 8"73;!T4'J(A M1LYM @²þ?Û¢é öluí¤ÂúîM(ì3810%_{"CR ø33&!} 3à¼È23&<'I!£×luí¤ÂúîA T4 'J(A M1LYM @²þ?Ë4Jæ«£ú=> I)J=38"CR øA T3bk<A50&<':8 - T4<A25&<'I!¹ø@´-pÏ= 3;(J"OP_U@ Crosby HF!T4-66&xB K8¿®èâ>¶Üy?Ë4J£×luí¤Â úî@ì@Ò<!M1LYM Aôf<A>/ T4f-òe@ôf=3;(J11%_"

JCOG<A T4'J(A M1LYM @²þ?Ë3 ;í¤Â±¤Ä?luúîM)d¢éölu í¤ÂúîM(!óø64.4&=ì3812%_"3 ,3!7KM´qJÍÔH@Û¢éöluí¤Â úî@ìM)0;!Û¢éöluí¤Âúî@ ÊÀÛý° M:8"óø68.3&!CR ø15&!2 à¼Èø31.5&<'I!d¢éöluí ¤ÂúîM´qJ»¾<':813%_" {Íu@½ÉHA!luúî@í¤ÂÆv oMEJ==F?~>¦"rMä0Jñ ×<!SU[^Xa=5FU M¡ÇÿÇÙõ4JÛ ¢éöluí¤ÂúîM:814%_"T4²þ?Ë 3 ; CR ø32&!T4M0² þ @ 2 à ¼ È27&< ':8"JCOG <F¡ÇÿÇÙõ@Û¢éölu í¤Âúî@ Phase II ý° 15%_->LK;+ I!§o-Ì8KJ" b´@ì,H!T4²þ?Ë4Jluí¤Âú Ø¸y@£ú$luí¤Âúî@áþ@£úMxD%

(3)

8AÉÎB¶×q}6¯ÔF8Q!*Ï¸±¶@ &ë6NJA=(N"Ï¸±¶AÂ³>/¼-LH<!ªìq}6¯ÔF8Q(·ªF>6F />+N"G8!OQÉ4<)N¿@B 6¯Ô»¯Bínz>3O</8"4-4!Þé LA5=B 5 K%14'&.OQÉ48.! 3KB CR Q÷LO<O.1 48>4<) N10&_{"G8!ÌÛLA5=B 5 K.OQÉ}

4<)8.!2KBªF@O.1 48>4< )N14&_{"OQ!*¼K@Ý6Nªìq}6¯} ÔF8AínJAóvß=(N" 2!N4"*+&'%02) û:Àö®~w%û:Àö}w&AÀö °_)==B!²NAÒ,a@K:<B N4 Aê@,]^[Ðîc>-ô;]^[Ðî c.GON"G8!q}6¯ÔF8QÍì@ ? * Medical oncologist L B!UICC A TNM .J@KM M1#l|îc>ê3ON,]^ [Ðîc!-ô;]^[ÐîcQÏ¸±¶Aí n¸zg¥>+<)N"72=!,]^[Ð îc!-ô;]^[Ðîc@;)<ªF7ÆQ xÑ6N" 1#,6&'%02) ,]^[Ðîc@;)<!P.AzudA =BP,{Ê!3 He{Ê@KNÍì@Ï¸ ±¶AÝ½>3O</8"Áäsþ?P,]^[ Ðîc=J!{ÊãâiÈ>=/N]^[Ðîc BÏ¸±¶Aín¸zg¥>B?L?)"E. RW^X$æm)h@,)<ªF×Äã=P,] ^[ÐîcBÈ>Äã3O8¼K@Ý6NÏ¸± ¶AÉÎB!Ï¸±¶Q#ê6NJA=B?-: 816&_{"p,Àö@;)<JîcBÈK=JÏ¸} ±¶A 5 ýËÚDB20'Qè+<,M17&_{!3 H} e{ÊQ!*ª±¶Aín>)+N" 2#7-39&'%02) -ô;%Celiac axis&]^[ÐEAîcJ TNM.J=B M1>3O<)N"p,ÀöÕA Ü)o2=B!M1a >)+C Celiac axis lympha-denopathyA2>>+LON"M.D. Anderson

-LAÀöÕ@Ý6N¶×q}6¯ÔF8A Ï¸K@;)<A5=B!ªF×@ EUS @KM -ô;]^[Ðîc>Äã3O8¼KA?B >b@+G=!l|îc¡ÿAZS]VU>) *ü.'A>4<)N18&_"T\^YA

Mars-manLB!EUS =-ô;]^[Ðîc>Äã3 O8¼K=BÏ¸K>%Ï¸ªFK@?AB <-:8>54<)N19& "P.=J!-ô;]^[ÐîcQl|]^[Ðîc>4<Ï ¸±¶Aín¸zg¥>+!q}6¯ÔF8Q Íì@?* Medical oncologist .Ø+N>¦ PON"P,]^[Ð>õ@Aó.'A>?N" 3#1/&'%02) ]^[Ðîc@;)<Bx9}ìaå@KNÅ ï91=B?0!îcÇ@KNÅïJµA >+LO<)N"Ü0A5BÏ¸K=A)C }ì]^[ÐîcÇ@KM?QL5NJA= (M!ªFy¤×AªF8ÖàA§(@?L?)" «©ðÞ}AtkL@KNªF×AI¹ÄãQ @485=B!¶ 5 ýËÚDB]^[Ðîc ÄãBÈÇ 4 `¾=17'!8 `¾=0'= (:820&_{"¡ÿ¬Bl|Ùîc.Ü0!q}} F8QI´}ìªFAÝ½>+LON" 3!IM"852( 3úîcBÀöM0¾$AøçAD>;>3 O!Àö°_)=@,)<J T g¥!N g¥! Mg¥>B4@!ùE48g¥>4<ê3O< )N"Åï@B"j3O?).!?+Gg¥ >3O<)N"ïÅÀö@Ý6N´}ìª FQ+N¿@B!7AÝ½@?N>+LO N"E.RW^X$)hAròL@KN521& =BÏ¸K@,1N7A*ïB15.3'>3O<) N"Ãáï.ÅI>>J@*ïBØr6N>3O N.!T1=JÚ£6N"IM BùE48?+Gg ¥>+LO!5ýËÚDBròLA5=B 11.9'=(M!¢AñÓLA522&_=J9'@¨ G:<)N"¡ÿ¬Bl|Ùîc.Ü0!q }F8QI´}ìªFAÝ½>+LON"P OPOB!3úîaA(N¼K@Ý4<¶×q} 2006ý%0É18ý&ï×û:ºqzu}wf´w

.

4 $

(4)

(÷S¤J;0!!¾E¯8B/>;23&_"

II!$%,(+.-'" Salvage )*

1!Salvage )*"#& Ã²mì+CÐ6?Llrö©Ä(÷0ÅÓ5 QP4A0Ï2BPAALC!fAíCÐ7 PÐ0ï#ABP"R0@E!Stage I D¸ä vCÐ6?LÁÜC¦Ülrö©Ä(÷0 RQ?.O24&_{!ðvCÐ7Pæ£|ÜëüÃ²} LÁÜCRQ?+P"9Dn!lrö©Ä (÷Dð¾DfAíCÐ6?Eæ£|Ü ëüÃ²0RQP4A0Ï+"&0TY_ Z#áñhDôóN25&_E16+DSõ6! ¦Ülrö©Ä(÷DfAí0ð¾@* QFÁÜCæ£|ÜëüÃ²S,H1<A6 ?+P" T2c¶D¸ävDlrö©Ä(÷DfA íCÐ6?E Salvage ¬°0RQP4A0Ë -?+P"¦Ülrö©Ä(÷D¼ºª@*P ÑÙL!lrö©Ä(÷D}±½%05NC ¶7PI@E Salvage ¸äÃ²0®rÜ¦(Cò m<A6?+P26&_{"èû¸äro@E2004éD}

Ò58pr°®oDV_]WU^'¸ävCÐ7P salvage surgery$Ûx/N¦(¿ÂI@$(C. +?!Salvage ¬°Sö©ÄÄ*50Gy c¶D¦ Ülrö©Ä(÷DfAíCÐ7P¦þ Ü¬°AÛx6;"¦þÜlrö©Ä(÷S³ ©Ä*50Gy c¶AÛx6!°Ælrö©Ä(÷D C"Û5Q;¸äÃ²¬°E Salvage ¬°A6 ?E«ObRB+A6;" lrö©Ä(÷CÁÜBÞ$ñhDÎ¶NE Ã²mìB´+C44Gy Dlrö©Ä(÷S+! !+30+CÊÄ*70Gy D¦Ülrö©Ä( ÷S+!9D,=D 4 +C Salvage ¬°S> ;27&_{"9DDõ@E!Ã²mìB T1-T2´+} D!+32+C¦Ülrö©Ä(÷S+!2 +C Salvage ¬°S+!1 +Eýí@41` ÀÍ6;28&_{"I;!T3-T4´+CL23+C¦Ü} lrö©Ä(÷S+!5+C Salvage ¬°S +!2+Eýí@17-19`ÀÍ6;29&_"4QN D´+@E¦(t,¢ùEý/>;Aõ6?+ P"aÖ0TY_Z#D¨ßN/NL!11+D Salvage ¬°0õ5Q?+P30&_"50)ÀÍws E30.8`@*>;"¬°ÈDçeàE³©Ä *MOL¹ÔàCz+Ét0*PA6?+P" &0TY_Z#áñh/NL 6 +D Salvage ¬° 0õ5Q?+P31&_{"2 +EX[_\'×!2 +} E-¿@*>;0!2+DýíÀÍ+Så NQ?.O!Salvage ¬°DÝjîÕD¥wD â0§5QP" 0TY_Z#DÉNE 5 +D Salvage ¬°S+ 4 +0ýíÀÍ6?+ PAõ6?+P32&_{"øòÇLB2!¬°t,} ¢ùLB/>;"áúÑrDyNE!¬°mì B50+CÐ6?¦Ülrö©Ä(÷S+!9 +CÐ6? Salvage ¬°S>;33&_{"Salvage ¬}

°EÇ+C{|k@>;"lrö©Ä(÷D JD´+.MGã¥wDÚ·¬°´+MOL! Salvage ¬°D´+C.+?ÀÍ%0ÿdC) @*>;" &0TY_Z#Øiñh@DÃ²mìB¸ä vCÐ7P¦Ülrö©Ä(÷D¿ÂSâ6 ;"ÐµE1998é/N2003éI@Clrö©Ä( ÷Sq¡6;259+D,Ì´+@*P"Stage I D 130´+D CR %E95)@*>;0!í032+C JNQ;"Salvage Ã²027+%24)&CRQ! 10+%37)&0¸äÃ²°@*>;"ÀÍ+104 +D,= 7 +%7)&0 Salvage ¸äÃ²S3? +;"Stage II!III D101´+D¦(nS» 1 C §7"CR %E65)@*>;0!í028+CJN Q;"Salvage Ã²023+%23)&CRQ!13 +%57)&0¸äÃ²°@*>;"ÀÍ+49+D ,= 8 +%16)&0 Salvage ¸äÃ²S3?+ ;"Stage IV D28´+D CR %E32)@*>;0! CR Ì+E 4 +<3@*>;"íCÐ6? vage Ã²ERQB/>;"fCÐ7P Sal-vage ¸äÃ²°0 3 +CRQ;"ÀÍ+E 6 + DJ@!,= 4 +E CR Ì+@*>;" Salvage Ã²S3;´+SuKlrö©Ä( ÷´+D¦(ÀÍ~ÄS» 2 C§7"9Q:Q D Stage C.+?!ãgwsC¸äÃ²°S3 àºvD¦(%lrö©Ä(÷Dê+D¦(SuK&

(5)

図 1 Stage I I，I I Iの治療効果図 2 Chemoradiotherapyの生存曲線 )Ke-GAOU?R,_X(0NP+B%/1 )" 2L-@Z&/!QI5^M[;,V(0H8 Cd+'*-4:aDRdb-SW.96QIE 2006]#`N18]$YT=\cJ4<96:7>3F7

"

#

!

(6)

表 1 食道切除術後合併症術前無治療 Salvage （n=185）（n=58）（28%） 51 （34%） 20 呼吸器合併症（18%） 34 （33%） 19 消化器合併症（4%） 7 （9%） 5 循環器合併症（11%） 21 （19%） 11 感染合併症在院期間（80%） 147 （59%） 34 30日以内（17%） 32 （29%） 17 31日以上（3%） 6 （12%） 7 在院死表 2 食道切除術後の気管気管支壊死穿孔予後他の因子再建経路頸部郭清気管支動脈症例死亡胸骨後あり切除 No.1 生存頸部縫合不全→縦隔炎胸骨後あり温存 No.2 死亡胸骨後あり切除 No.3 死亡胃管先端壊死→縦隔炎後縦隔あり温存 No.4 死亡胃管先端壊死→縦隔炎後縦隔なし温存 No.5 ©@ÂÌ>çÑ3L",{Ê:-L;*JM 5"2+2!¬=+J?°-> Salvage ½«,N M!¼Ç-> Salvage ½«°-,È.xCML0 ;+J!½«jà¶Úy>É3Lhsõ¡Á*ö :A`;ã>É3L Salvage ¢©>ILót ,ëj:'L;*JM5"

2!Salvage $%"#'&

hsõ¡Á*ö@½«¢©>AË-=[SR Oä)"Cleveland Clinic +JA¶Ú½«©@ ù&,©Ãü*5.9&>É2945Gy @©Ãhs õ¡Á*ö15.7&;ô29(L34%_"©Ãhs

õ¡Á*ö@©ù@a@È.,}zð °:'K!îí÷ëÅH}zð°OJ 35F>õ¡Á¯¡þ=<Oò25;29( L"YZ\X\@ Siewert @¾+JA!©Ãhs õ¡Á*öAº³o>IL|u|u1, ÿ^>È.!ù&,(;ô29(L35%_" º³o@É;29!|uÙû@gÇ>8( 9@×ÕJ@ï36%_{Ob#29(L,!£0@¿} ~í^H¹Ô>IKgÇ,Ü=µ,È(;2 9(L" ECOG:=NM560Gy @©Ãhsõ¡Á* ö:A16&@¢©w.ùOÝF9(L37%_"C 5!õ¡ÁÁ+OÁ+>3L,:A! º,±ý1M=+755F38%_!ñ:AÒh sõ¡Á*ö@õ¡ÁÁ+A50Gy ;1M9(L" ñ@ MD Q\W#U\@ Swisher JA13-@ Salvage¶Ú½«Oô2539%_{"©Ãhsõ¡Á} *ö;æp2!Òhsõ¡Á*ö@ Sal-vage¶Ú½«A¯¡Á+,È.!¯¡¦)+J @{v,Ð(5F>!¢©,Ü2.=Kð°, Æi3L;25"¢©ù&A15&:'K!Óf A·¨>29¶Úy¢©@øì=¾:= )B-6;29(L"1J> Medical oncologist >É29A!60Gy OÏ*LÁ+A"OnÄ2 =(6/:=.!Salvage ¶Ú½«,è$>=7 5µ>[SROÆi14L@:ÂÌ3B-:A =(;29(L" ',PT\V#Îeêc: Salvage ¶Ú½« O75°->8(9© ;ð°OØ25" É²A1997Þ+J2004ÞC:> Salvage ¶Ú½« O¤/558-;©Ãü*:¶Ú½«O¤/5 185-:'L"Salvage ¶Ú½«:A!ð°,È .!c,10&]´>D;FJM!c{vG Ð.=75$é 1 %"Salvage ¶Ú½«:A!ål ¸ú/!ád!|u|u@m;À!§r d,È.!¨Û+8ÍÒkO®(5"|u| u@m;ÀA2íq»O=(|uÙû gÇ,ëà:'75°->ã¼2!|Ú@(³ o>IL;*JM5"2íq»>IL2í|u ¥_@â%;u½%,|Ú@(³oOªÐ2 5jàº,'L"C5!|uÙûgÇ-:G§ Ö¹y@*$hsõ¡Á*ö@ß-@*OxE%

(7)

図 3 食道切除術後生存曲線 s`NìÉ3L<zuzu¥?i§<ËNÉ2 7$ó 2 %"íhÃ%7?ìÉ-Ù/!dtý¬ Ì2ÿ?9d>ILíhÃ°U?®µÔ ?éÆ-*JM7"6;@!!ï c65;zuzu¥?i§<Ë!²s` -Ù,97" Salvage ÁèÊ·<µÏ(©2ÁèÊ·?µ ÉÖÌNæ17$Å 3 %"Salvage ÁèÊ·; ?µà?ÉÖ.?ác@10&S¾?]§". -\<*JM7"6??ÉÖÌ@µÏ( ©2ÁèÊ·?ÉÖÌ<ú>,97" S¾?æ,J!Salvage ÁèÊ·µ;@] §?\<=Lzuzu¥?i§HË<²s` ?wN117µª?ÎÛ-³-;'L" 3!Salvage &'#'%&$ ý¬Ì»¬*;@ÒÀ?ÍVd<0½o>I L9dNÉ2L!»¬÷T?£,@;.LK ð0:N=)ñ--'L40%_"WN,(: N=)¿>@!ø÷T<=LÁèÕ<W Õ?ÓþC?ý¬Ì»¬?_N11=0MA =J=("/-OPRQ#åô]?¡âJ41%_@! Salvage ®µ;@ø÷?!õÑ-Ý§ãù ¼?\<=L<1:(L">@^ÕßN ,(uøNöe1:0jÐN@,K!ø ÷!õÑN#¦;.7<ü17"å}¶¤Y Ú?ÞØJ@!50Gy S¾?dtý¬Ì2ÿ? Salvage ÁèÊ·275N!45Gy Sc?µÏdtý ¬Ì2ÿ?ÁèÊ·285<îq1742% "Sal-vage ÁèÊ· 2 5<µÏdtý¬Ì2ÿ 1 5> ]§"-'K!(4MG 3 4ZrÈ5;'97 7F!dtý¬Ì2ÿ?ÁèÊ·;@´¹®µ >3D.<1:(L" /-OPRQ#Þaô];G(E8>¨ ?Üm;'L-!ò-9:(L Sal-vage ÁèÊ·µ?®µ®|N{3L"dtý¬ Ì2ÿ;@Áè°U!²s?9d>IKX¢ ¯8<ÍVd?û-é;'K!T3¼5;@z u!zu¥!Úç'!Â&<?~kG)3;=(" ¾÷Áèv?zu&+÷×¸Hc÷Áèv?Â& ùÊ·G1:+K!^l-ñÄ<*L" íhÃ°U+IBzu¥ç'°U?p«=Ô ?7F>G^l-,5=("zuzu¥? 0bÖ?7F>^zu¥ç'N;.LKbÖ 2006ë$úÇ18ë%äÏyê$ºdxnftg[±g

(

)

"

(8)

7R"k®ü9Cpé/*s#CË£BD! kâ®ü9CpéC:LB!.,bc aÚC{ÔD:P.Aùg/A2SE¡TA*" ¨®ü9Upé7R:LB!íü9qC{ ÔD:P.Aùg/A2SE¡TA*"qÍà ü9.PP,GCFUpé7R:LB!P ,{ÔD:P.Aùg/A2SE¡TA*" Ïý¹fåÎCßhrN§rBOQÏýØÃ BÏýÅ/<FS8° ?AQN7*"P,/£ C5£*ä/½|BFÿ5½|mU&Õ5! ÝUÕ6:ÇJU5:"ý$çC° C ¼øU<öB½|L>ªU¡+O+B5: /!iÛï,Cw°.P&Õ5:½|mBOQ ÝUÕ6=³;:ÇJU5=-Q!¦ ARû/(A>)R"P,ÏýGC3µÞ ÆµClUH5!/£,D>0RQç? 7R"q,Ïý>DÆµ>/ië,BF? ,PS!iC¬Ó>Di0=,!ëÊ,ÄMç DØÃ5!¨ií;ü9CiíMFÿ,ôÊU/ £,?7R"/£,5£*ä/Õ6:?0C½| GClUH5!/£,?½|CBiíM çC8åÎU¼ø7R"

III!+-.,0

1!&')( Z]c_GðDJBì5=Ù·Us# B7R?S:±I4>)Q!eâB¡ATS=* :`XaZ¸ÀDH?V@¡TSA1A;:" í}CÖêPD!þ7Ïý´~vBÂè7 R3µÞ±I,=Bì5=!3µÞÆµâBÏý Z]c_Uæÿ5:ÇJC£1ÇB<*=Wc Y$_ó©U¡;:43'_{"47ÇJòC51(B£1Ç} U!L!21(C±IK°6C>);:?2¤5 =*R"I:!¥D/V[c\$òn)jC» PD!r}3µÞI4B self-expandable metal-lic stentUGð5:22JB<*=2¤5:44'"õ uÉyDxã5ODB4S:/!íü9ÑÁ JC75(B¿°U!L:"r}3µÞI4/ 1¡ATSRO+BA;:«!Z]c_GðD r}3µÞI4CtUz!5:Ê>û7R (A/)R"

"%$#

T/¥>Mr}3µÞI4/1+5!r} 3µÞI4UåJ£T9:º}ö±I'0BD! ÏýC±IÜEDåJD=PSA*"r}3µ ÞI4>D!Ð%#GC-¬@UH7R?? MB!däAÏýØÃ¸ÀC:LC÷oUû7 R3?/(A>)R"~¶BÌ2?áî¯U²7 :LBM!Ès#A^$\Uñ×7R3?/¾ A>)R"

/ *

1'Yano M, Tsujinaka T, Shiozaki H, et al. Con-current chemotherapy&5-fluorouracil and cis-platin'and radiation therapy followed by sur-gery for T4 squamous cell carcinoma of the esophagus. J Surg Oncol. 70#25%32, 1999. 2' Yano M , Shiozaki H , Tsujinaka T , et al .

Squamous cell carcinoma of the esophagus infiltrating the respiratory tract is less sensi-tive to preoperasensi-tive concurrent radiation and chemotherapy . J Am Coll Surg . 191# 626%634, 2000.

3'Noguchi T, Moriyama H, Wada S, et al. Re-section surgery with neoadjuvant chemora-diotherapy improves outcomes of patients with T4 esophageal carcinoma. Dis Esopha-gus. 16#94%98, 2003.

4'Ikeda K, Ishida K, Sato N, et al. Chemoradio-therapy followed by surgery for thoracic esophageal cancer potentially or actually in-volving adjacent organs . Dis Esophagus . 14#197%201, 2001.

5'Fujita H, Sueyoshi S, Tanaka T, et al. Pro-spective non-randomized trial comparing esophagectomy-followed-by-chemoradiothe-rapy versus chemoradiotheesophagectomy-followed-by-chemoradiothe-rapy-followed-by- chemoradiotherapy-followed-by-esophagectomy for T4 esophageal cancers. J Surg Oncol. 90#209%219, 2005.

(9)

6&Fujita H , Sueyoshi S , Tanaka T , et al . Esophagectomy " is it necessary after chemoradiotherapy for a locally advanced T4 esophageal cancer? Prospective nonran-domized trial comparing chemoradiotherapy with surgery versus without surgery. World J Surg. 29"25$31, 2005.

7&Hagry O, Coosemans W, De Leyn P, et al. Ef-fects of preoperative chemoradiotherapy on postsurgical morbidity and mortality in cT3-4'!( cM1lymph cancer of the oesophagus and gastro-oesophageal junction. Eur J Car-diothorac Surg. 24"179$186, 2003.

8&Stahl M , Stuschke M , Lehmann N , et al . Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus . J Clin Oncol . 23"2310$2317, 2005.

9&Ohtsu A, Yoshida S, Boku N, et al. Concur-rent chemotherapy and radiation therapy for locally advanced carcinoma of the esophagus. Jpn J Clin Oncol. 25"261$266, 1995.

10&Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and!or M1 lymph node squamous cell carcinoma of the esopha-gus. J Clin Oncol. 17"2915$2921, 1999. 11&Crosby TD, Brewster AE, Borley A, et al.

Definitive chemoradiation in patients with in-operable oesophageal carcinoma . Br J Can-cer. 90"70$75, 2004.

12&Ishida K, Iizuka T, Ando N, Ide H. Phase II study of chemoradiotherapy for advanced squamous cell carcinoma of the thoracic esophagus"nine Japanese institutions trial. Jpn J Clin Oncol. 26"310$315, 1996.

13&Ishida K, Ando N, Yamamoto S, Ide H, Shi-noda M . Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus" a Japan Esophageal Oncology

Group% JEOG &!Japan Clinical Oncology Group trial%JCOG9516&.Jpn J Clin Oncol. 34"615$619, 2004.

14&Nishimura Y, Suzuki M, Nakamatsu K, et al. Prospective trial of concurrent chemoradio-therapy with protracted infusion of 5-fluo-rouracil and cisplatin for T4 esophageal can-cer with or without fistula. Int J Radiat Oncol Biol Phys. 53"134$139, 2002.

15&JCOG Y`cLIdC?05#2 NX)/ 05#2 JCOG0303%phaseII!III&BKOEA [NX)/,T*. Low Dose Cisplatin!5-FU!^HQWG\ab_+ Standard Dose Cisplatin!5-FU!^HQWG\ab_+-4 6138U II!III SFD

16&Tachimori Y, Kato H, Watanabe H. Surgery for thoracic esophageal carcinoma with clini-cally positive cervical nodes. J Thorac Car-diovasc Surg. 116"954$959, 1998.

17&Igaki H, Kato H, Tachimori Y, Sato H, Daiko H , Nakanishi Y . Prognostic evaluation for squamous cell carcinomas of the lower tho-racic esophagus treated with three-field lymph node dissection . Eur J Cardiothorac Surg. 19"887$893, 2001.

18&Malaisrie SC, Hofstetter WL, Correa AM, et al. Endoscopic ultrasonography-identified ce-liac adenopathy remains a poor prognostic factor despite preoperative chemoradiother-apy in esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 131"65$72, 2006.

19&Marsman WA, van Wissen M, Bergman JJ, et al. Outcome of patients with esophageal carcinoma and suspicious celiac lymph nodes as determined by endoscopic ultrasonogra-phy. Endoscopy. 36"961$965, 2004.

20&Natsugoe S, Yoshinaka H, Shimada M, et al. Number of lymph node metastases deter-mined by presurgical ultrasound and endo-scopic ultrasound is related to prognosis in 2006Z%]P18Z&VR>Y`M8=;9<:@7J:

"

#

!

(10)

patients with esophageal carcinoma . Ann Surg. 234#613$618, 2001.

21&Kato H, Tachimori Y, Watanabe H, et al. In-tramural metastasis of thoracic esophageal carcinoma. Int J Cancer. 50#49$52, 1992. 22&Yuasa N, Miyake H, Yamada T, et al.

Prog-nostic significance of the location of intramu-ral metastasis in patients with esophageal squamous cell carcinoma. Langenbecks Arch Surg. 389#122$127, 2004.

23&Hokamura N, Kato H, Tachimori Y, et al. Pre-operative chemotherapy for esophageal car-cinoma with intramural metastasis . J Surg Oncol. 75#117$121, 2000.

24&Kato H, Udagawa H, Togo A, et al. For the Japan Clinical Oncology Group%JCOG&. A phase II trial of chemo-radiotherapy in pa-tients with stage I esophageal squamous cell carcinoma#Japan Clinical Oncology Group study%JCOG9708&Abstract No#1147 Proc Am Soc Clin Oncol. 22#286, 2003.

25&Hattori S, Muto M, Ohtsu A, et al. EMR as salvage treatment for patients with locore-gional failure of definitive chemoradiother-apy for esophageal cancer. Gastrointest En-dosc. 58#65$70, 2003.

26&Ohtsu A. Chemoradiotherapy for esophageal cancer#current status and perspectives. Int J Clin Oncol. 9#444$450, 2004.

27&Murakami M, Kuroda Y, Okamoto Y, et al. Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma. Int J Radiat Oncol Biol Phys. 40# 1049$1059, 1998.

28&Murakami M, Kuroda Y, Nakajima T, et al. Comparison between chemoradiation proto-col intended for organ preservation and con-ventional surgery for clinical T1-T2 esopha-geal carcinoma. Int J Radiat Oncol Biol Phys.

45#277$284, 1999.

29&Murakami M, Kuroda Y, Matsusue S, et al. Treatment results of esophageal carcinoma of clinical T3, T4M0#historical comparison between neoadjuvant chemoradiotherapy followed by surgery or definitive radiother-apy and conventional surgery . Oncol Rep . 7#571$578, 2000.

30&_y;O!L8dY"'i}@^.)*1 controversy(i } @ . ) * 1 salvage sur-gery f=: 57#191$198, 2002. 31&M|ywm!puNn!CyeZ!v"F =:/[l S^x`s9>M/i} @EVac F=: 55#743$745, 2002. 32&Utj!Hy I!qBJ~!rW;P! R{oN S^x9>`sM. sal-vageac2\Q+,Fi}@h g9A=:><X] 37#1378$1383, 2004. 33&DWbC!K k '@^.)*1UG/ 67534(i}@ S^x9>`s - Salvage ac =:><X] 105# 485$488, 2004.

34&Chidel MA, Rice TW, Adelstein DJ, et al. Re-sectable esophageal carcinoma#local control with neoadjuvant chemotherapy and radia-tion therapy. Radiology. 213#67$72, 1999. 35& Bartels HE , Stein HJ , Siewert JR .

Tra-cheobronchial lesions following oesophagec-tomy#prevalence, predisposing factors and outcome. Br J Surg. 85#403$406, 1998. 36&Fujita H, Hawahara H, Yamana H, et al.

Me-diastinal lymph node dissection procedure during esophageal cancer operation$ care-fully considered for preserving respiratory function. Jpn J Surg. 18#31$34, 1988. 37&Keller SM, Ryan LM, Coia LR, et al. High

dose chemoradiotherapy followed by gectomy for adenocarcinoma of the esopha-gus and gastroesophageal junction#results of a phase II study of the Eastern Coopera-RzkQ@/^%9>`s/T/^2?0&

(11)

tive Oncology Group . Cancer . 83" 1908 $ 1916, 1998.

38&Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123% Radiation Therapy Oncology Group 94-05& phase III trial of combined-modality therapy for esophageal cancer" high-dose versus standard-dose radiation therapy. J Clin Oncol 20"1167$1174, 2002. 39&Swisher SG, Wynn P, Putnam JB, et al.

Sal-vage esophagectomy for recurrent tumors after definitive chemotherapy and radiother-apy. J Thorac Cardiovasc Surg. 123"175$ 183, 2002.

40&C7QN!I;=J!>DM3 '6A @H 9<(+/SQ!+/P8ESQ5)@H09 < 9< 53"1571$1575, 1999.

41&Sakuraba M, Kimata Y, Hishinuma S, et al. Importance of additional microvascular anas-tomosis in esophageal reconstruction after salvage esophagectomy. Plast Reconstr Surg.

113"1934$1939, 2004.

42&Nakamura T, Hayashi K, Ota M, et al. Sal-vage esophagectomy after definitive chemo-therapy and radiochemo-therapy for advanced eso-phageal cancer. Am J Surg. 188"261$266, 2004.

43&Nishimura Y, Nagata K, Katano S, et al# Japanese Society for Esophageal Diseases . Severe complications in advanced esopha-geal cancer treated with radiotherapy after intubation of esophageal stents"a question-naire survey of the Japanese Society for Esophageal Diseases. Int J Radiat Oncol Biol Phys. 56"1327$1332, 2003.

44&Sumiyoshi T, Gotoda T, Muro K, et al. Mor-bidity and mortality after self-expandable metallic stent placement in patients with pro-gressive or recurrent esophageal cancer af-ter chemoradiotherapy. Gastrointest Endosc. 57"882$885, 2003.

2006